These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The brand has added a range of exciting new products especially formulated for oily skin.
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Subscribe To Our Newsletter & Stay Updated
